

Antibody Formation in Dysgammaglobulinemia *

GERALD J. GLEICH,† JONATHAN W. UHR, JOHN H. VAUGHAN,‡ AND
HARRY A. SWEDLUND

(From the Department of Medicine and Microbiology, University of Rochester School of Medicine and Dentistry, Rochester, N. Y.; the Irvington House Institute and Department of Medicine, New York University School of Medicine, New York, N. Y.; and the Mayo Clinic, Rochester, Minn.)

Immunization of patients with type I dysgammaglobulinemia, in which a deficiency of γ G- and γ A- and an increase in γ M-globulins exists, has usually resulted in production of γ M antibodies (1-6). In most instances, however, the techniques employed for the measurement of antibody activity have been semiquantitative, and in some cases it has been difficult to distinguish the antibody activities produced by the patient from those contained in the γ G given as treatment. Careful study of antibody formation in this syndrome seemed of interest because of the relationship between γ M and γ G antibody formation (7-10) and also because of the possibility that a unique opportunity would be provided to obtain evidence in man of whether immunological "memory" might be exhibited with γ M antibodies. Studies in animals have suggested that γ M antibody formation does not lead to persisting immunological memory (11, 12).

Antibody formation in a previously reported patient (5) with type I dysgammaglobulinemia was examined further by immunization with bacteriophage ϕ X 174 (ϕ X). Because ϕ X is highly antigenic and the assay for antibody is sensitive and quantitative (13, 14), this immunization system is advantageous for investigation of the im-

mune response in patients with impaired antibody formation (15, 16).

Methods

Patient. The patient, J. T., had a γ M concentration of 1.8 g per 100 ml and γ G and γ A concentrations of less than 2 mg per 100 ml as determined by immunodiffusion analysis. The concentration of γ D in the patient's serum¹ was less than 0.003 mg per ml (normal concentration, 0.02 to 0.05 mg per ml). Although γ G was not identified by immunoelectrophoresis or by micro-Ouchterlony double diffusion of the patient's serum obtained before treatment with Red Cross γ -globulin, its presence was demonstrated by Preer double diffusion (18); trace amounts of this immunoglobulin were therefore present. During the current study, the patient was receiving Red Cross γ -globulin (γ G) as treatment, 16 ml or 2.64 g every 6 weeks. From day 191 to day 321 (Table I), γ G therapy was discontinued. The γ G concentration in the patient's serum during this interval declined to less than 7 mg per 100 ml. One lot of γ G used for therapy was tested for anti- ϕ X activity and none was demonstrated.

Measurement of serum immunoglobulins. During the period of study γ G- and γ M-globulins in the patient's serum were measured by single diffusion (Oudin) as described by Rubinstein (19) with antisera specific for human γ G-, γ A-, and γ M-globulins (20).

Antigen. The preparation of the bacteriophage ϕ X has been described previously (15).

Immunization. The patient was immunized by intramuscular injection in the deltoid area of 0.1 ml of a phage preparation containing 10^{11} particles per ml. Blood was obtained by venipuncture at intervals after immunization.

Antibody titrations. The assay for antibody was carried out by the methods described by Adams (21).

Physicochemical characterization of antibody. Density gradient ultracentrifugation was performed with a Spinco model L ultracentrifuge and the SW-39L swinging-bucket rotor. Five-tenths ml of a 1:2 dilution of whole serum was layered on a gradient of 10 to 40% sucrose prepared by a density gradient sedimentation de-

* Submitted for publication August 16, 1965; accepted May 16, 1966.

Supported in part by grants Am 02443, AI 28-03, AI 02349, and AI 01821 from the National Institutes of Health; by the Office of the Surgeon General, Department of the Army; and by the Commission on Immunization of the Armed Forces Epidemiological Board.

Presented in part at the Twenty-first Annual Meeting of the American Academy of Allergy, Bal Harbour, Fla., February 15-17, 1965.

† Address requests for reprints to Dr. Gerald J. Gleich, Mayo Clinic, Rochester, Minn.

‡ Recipient of a Career Research Award from the National Institutes of Health.

¹ Determined by Drs. David Rowe and John Fahey (17).

vice² and centrifugation carried out for approximately 16 hours. To ensure that material from the upper portions of the tube was not contaminated with material from the lower portions (12, 22), we removed 10 fractions by means of capillary pipettes from the top of the tube and 6 fractions through a perforation at the bottom of the tube. Marker proteins of known sedimentation coefficient were added to the sample to establish the approximate sedimentation coefficients of the various fractions. The marker proteins included aldolase, 8 S³; catalase, 11 S⁴; and rabbit thyroglobulin, 19 S.⁵ Evans blue dye was added to identify the serum albumin, 4 S. Catalase was assayed as described by Chance (23 cf. 24). Aldolase was assayed as described by Allen, Sirisinha, and Vaughan (24). Thyroglobulin was detected by micro-Ouchterlony immunodiffusion analysis with a dog antithyroglobulin serum.⁵ γ G, γ A, and γ M proteins were identified in micro-Ouchterlony immunodiffusion analysis with antisera specific for the corresponding immunoglobulins. The preparation of these antisera has been described by Leddy, Hill, Swisher, and Vaughan (20). The results shown in Figure 2 were obtained as indicated above, except that fractions of 0.24 ml were collected with the Isco density gradient fractionator.⁶ IgM was quantitated by radial diffusion (25) with anti- γ M immuno-plates.⁷

Gel filtration on G-200 Sephadex was performed with a 0.8 × 113-cm column equilibrated in 1.0 M NaCl, 0.1 M pH 8.0 Tris-HCl. One ml of normal serum or the patient's serum was applied and eluted with the same buffer. One-ml fractions were collected, and their absorption at 277 m μ was determined. The fractions were analyzed for immunoglobulins by micro-Ouchterlony double diffusion employing antisera specific for γ G, γ A, and γ M.

Antibody was also treated with 2-mercaptoethanol (2-ME) as previously described (11). Antibody activity destroyed by 2-ME treatment was presumed to be 19 S, whereas that resistant to such treatment was presumed to be 7 S (26).

Results

The results of immunization of the patient with ϕ X are shown in Table I. Serum obtained before immunization did not contain detectable anti- ϕ X activity. Fourteen days after immunization, the serum k (the rate constant of phage inactivation) for anti- ϕ X was 4.37, and all of this antibody activity behaved as 19 S. At 14 days, a second injection of 10¹⁰ ϕ X was given, and at 28 days the serum k was 14.3. Again all of the antibody ac-

² Densigrad, Buchler Instruments, Fort Lee, N. J.

³ Calbiochem, Los Angeles, Calif.

⁴ Worthington Biochemical Corp., Freehold, N. J.

⁵ Generously provided by Dr. Douglas Johnstone.

⁶ Model D, Instrumentation Specialties Co., Lincoln, Neb.

⁷ Lot 7022A6, Hyland Laboratories, Los Angeles, Calif.

TABLE I
Immunization of J. T. with bacteriophage ϕ X 174

| Day | Dose of ϕ X* | Serum antibody (k) [†] | | Serum immunoglobulins | |
|-----|----------------------|---------------------------------|--------|-----------------------|------------|
| | | 19 S | 7 S | γ G | γ M |
| 0 | 1 × 10 ¹⁰ | <0.01† | <0.01† | 94 | 1,210 |
| 14 | 1 × 10 ¹⁰ | 4.37 | <0.01† | | |
| 28 | | 14.3 | <0.01† | | |
| 114 | | 0.187 | 0.388 | | |
| 147 | | 0.092 | 0.298 | | |
| 177 | 1 × 10 ¹⁰ | 0.006 | 0.224 | 111 | 2,010 |
| 191 | | 23.2 | 2.21 | | |
| 307 | 1 × 10 ¹⁰ | 0.14 | 0.5 | 188 | 1,695 |
| 321 | | 138.6 | 22.2 | | |
| 937 | 1 × 10 ¹⁰ | <0.01† | 0.19 | 111 | 1,550 |
| 951 | | 320 | 240 | | |

* Number of plaque-forming particles injected.

† Here the identification of antibody activity as 7 S or 19 S was based on its susceptibility to 2-mercaptoethanol (2-ME). k is the rate constant of phage inactivation.

‡ Similar k with or without 2-ME.

tivity behaved as 19 S. These results confirmed previous studies of the patient's immune response, in which only 19 S antibodies were produced (5). At 114 days, the serum antibody activity had declined to a total k of 0.575, but now antibody behaving in 2-ME as 7 S was detected. At 147 and 177 days, the serum k declined further, and by 177 days virtually all of the small residual antibody activity was of the 7 S type. At this time a third injection of 10¹⁰ ϕ X was given and 14 days later antibody activity again assayed. There were marked increases in both the 19 S and 7 S activities. Analysis of the 191-day serum by sucrose density gradient ultracentrifugation revealed the presence of slowly sedimenting and rapidly sedimenting antibody activities. As shown in Table II the slowly sedimenting antibody activity was resistant to 2-ME treatment, whereas the rapidly sedimenting antibody activity was largely destroyed by 2-ME treatment. By 307 days, the serum k value had declined to 0.64, with 0.5 as 7 S. After a fourth injection of ϕ X on day 307 marked in-

TABLE II
Anti- ϕ X 174 activity of 191-day serum

| Antibody activity (k) | | | | | |
|-----------------------|-----------|----------------|-----------|---------------|-----------|
| Whole serum | | 19 S fraction* | | 7 S fraction* | |
| With-out 2-ME | With 2-ME | With-out 2-ME | With 2-ME | With-out 2-ME | With 2-ME |
| 23.0 | 2.20 | 0.57 | 0.027 | 0.019 | 0.018 |

* Approximate, as determined by sucrose density gradient ultracentrifugation.




FIG. 1. SUCROSE DENSITY GRADIENT ULTRACENTRIFUGATION OF J. T.'S SERUM ON DAY 191.

creases in both 7 S and 19 S activities were noted; the 19 S antibody activity at this time was 31-fold greater than it had been after primary immunization (day 14). During the period from day 28 to day 177 the biological half-times, i.e., the resultant of synthesis and degradation, for the 19 S and 7 S antibody activities were 13 days and 80 days, respectively. Finally, on day 937 when 19 S antibody was not detectable, a fifth injection of $\emptyset X$ was given. There were striking increases in both

the 19 S and 7 S antibody activities. The 19 S antibody activity was now 73-fold greater than after primary immunization.

The nature of the slowly sedimenting anti- $\emptyset X$ activity in the 191-day serum was examined further by sucrose density gradient ultracentrifugation and immunodiffusion analysis with antisera specific for γG , γA , and γM . These results are shown in Figure 1. Protein reacting with anti- γM was identified both in the 19 S fractions and also in the 7 S fractions. γG , passively acquired as treatment, was identified only in the 7 S fractions. As shown in Figure 2, gel filtration of the patient's serum on Sephadex G-200 also revealed protein reacting with anti- γM in the 7 S region. Noteworthy is the virtual absence of a 7 S peak in the patient's serum for contrast.

These studies indicate that the patient's serum contained slowly sedimenting (approximately 7 S) γM protein. This observation could have been caused by inadequate separation of 19 S γM from 7 S proteins because of the increased concentration of γM in the patient's serum. Density gradient ultracentrifugation of serum from a patient with macroglobulinemia showed, however, that even in the presence of a γM concentration of 3 g per 100 ml, 7 S γG - and 19 S γM -globulins could be adequately separated. Furthermore, when the fractions containing light γM from the patient were recentrifuged, the γM again sedimented in the 7 S area. Finally, as shown in Figure 3, repeat examination of the patient's serum by density gradient ultracentrifugation and analysis of the fractions for their concentrations of γM revealed two major




FIG. 2. GEL FILTRATION ON SEPHADEX G-200 OF J. T.'S SERUM OBTAINED ON DAY 191.




FIG. 3. REPEAT DENSITY GRADIENT ULTRACENTRIFUGATION OF J. T.'S SERUM.

peaks of γ M protein, one faster and one slower than the 11 S catalase marker. These observations appear to exclude the possibility that the presence of the light γ M was due simply to contamination of the 7 S area with 19 S γ M-globulins and indicate that two populations of γ M molecules were present in the patient's serum.

Since many of the sera employed in this study had been stored at -10° C for periods up to several months, the possibility that the 19 S γ M might have depolymerized to 7 S subunits was considered. Studies in our laboratory suggested that this may occur at least at 4° C, in the case of certain pathological macroglobulins (27). To examine this question, we subjected a sample of serum freshly taken from the patient to sucrose density gradient ultracentrifugation. The presence of γ M was again demonstrated in fractions from the 7 S area. This observation demonstrates that the light γ M was not related to prolonged storage of serum or to repeated freezing and thawing.

To determine whether the light γ M possessed antibody activity, we examined its ability to neutralize ϕ X. Serum obtained on day 191 containing anti- ϕ X activity in the slowly sedimenting fractions was separated by density gradient ultracentrifugation, and the fractions from the 7 S area were pooled and dialyzed against saline. In these separations the patient's isoagglutinin, anti-B, served as a marker for the 19 S-containing fractions, and the therapeutically administered Red

Cross γ G-globulin served as a marker for the 7 S fractions. The 7 S pool was divided into 5 fractions and treated as shown in Table III. One fraction was absorbed with anti- γ G, a second fraction with anti- γ A, and a third fraction with anti- γ M. To the fourth fraction, 13 μ g N egg albumin was added, and this was absorbed with anti-egg albumin. This fraction served as a control for non-specific effects of immunoprecipitation. A fifth sample served as a control to indicate the starting quantity of antibody. All of the antisera employed in these absorptions were shown by prior analysis to be free of anti- ϕ X activity. As indicated in Table III, absorption with anti- γ G essentially completely removed the anti- ϕ X activity. Absorption with anti- γ M and anti- γ A reduced the activity by approximately 50%. These latter reductions may reflect the presence of specific antibody in the γ A and the slowly sedimenting γ M, or they may have been due to residual anti- γ G activity in the absorbed anti- γ M and anti- γ A sera. It appears, at any rate, that the 7 S neutralizing antibody was associated principally with the γ G class of immunoglobulins; trace quantities of this class had been demonstrated in the patient's serum before any treatment with Red Cross γ G-globulin. These separations and analyses were repeated on another occasion, and essentially the same results were obtained.

Discussion

Immunization of patients having type I dysgammaglobulinemia (1-6) with antigens such as typhoid vaccine, tetanus toxoid, and poliomyelitis (Salk) vaccine has, in general, resulted in rather low levels of antibody activity. However, these

TABLE III
Absorption of J. T.'s "7 S" fraction from density gradient ultracentrifugation

| Antiserum used for absorption | k |
|-------------------------------|---------|
| Anti- γ G | <0.0005 |
| Anti- γ A | 0.0080 |
| Anti- γ M | 0.0096 |
| Anti-EA* | 0.0150 |
| Control | 0.0170 |

* 13 μ g N crystalline egg albumin (EA) added before absorption.

patients have often shown strikingly high titers of 19 S isoagglutinins against A or B erythrocytes, as was true also with our patient (5). Against typhoid, our patient produced low titers of 19 S anti-H and anti-O, and these titers remained low and as 19 S on reimmunization. The insensitivity and the semiquantitative nature of this agglutinin assay, however, prompted the present further investigation with $\emptyset X$.

The antibody response to $\emptyset X$ in normal humans and other mammals consists of an initial short-lived formation of rapidly sedimenting (19 S) antibodies and a later longer-lasting formation of slowly sedimenting (7 S) antibodies (11). Immunological memory has been demonstrated for both 19 S and 7 S antibodies. However, the "memory" associated with 19 S antibody is usually transient; it was no longer demonstrable in guinea pigs when the interval between the first and second stimulation was 1 month, whereas that associated with 7 S was persistent for a minimum of 1 year. Similar results have been obtained in studies with poliovirus (12). In contrast to these results, Nossal, Ada, and Austin (28) have obtained 19 S immunological memory by challenging rats with minute amounts of flagella antigen followed 6 weeks later with a larger dose. Also, Borel, Fauconnet, and Miescher (29) obtained a 19 S anamnestic response in neonatal rabbits immunized with human red blood cells.

The immune response to $\emptyset X$ in the present patient differed from that in normal subjects in several respects. First, the predominance of 7 S antibody usually seen with prolonged immunization did not occur, and most of the antibody found was 19 S even after the fifth injection of antigen. Seven S antibody was produced only late in the course of immunization but then in increasing amounts. Most of the 7 S anti- $\emptyset X$ activity was associated with γG as demonstrated by its removal after absorption with a specific anti- γG serum. Secondly, the duration of synthesis of 19 S antibody appeared to be prolonged, as shown by the half-time of 13 days during the period from day 38 to day 177. The biological half-time of γ_1 -macroglobulin in normal human subjects as determined by Barth, Wochner, Waldmann, and Fahey is 5.1 days (30). Finally, the increase in the level of 19 S antibody after the third injection of antigen was suggestive of slight immunological

memory. This was demonstrated more strikingly after the fourth and fifth injections of antigen, when the level of 19 S antibody was 31- and 73-fold, respectively, greater than after primary immunization.

The existence of long-lived 19 S immunological memory in this patient may reflect an intrinsic abnormality of her 19 S antibody synthesizing mechanism. Another possibility is that our patient's immunological status was changing during the rather long period of study. That this may occur is shown by the observations of Rosen and his colleagues (1) on a patient (F. E.) with congenital agammaglobulinemia who inexplicably began to produce measurable amounts of γM protein. Repeated analysis of the immunoglobulins of our patient during the past 3 years (see Table I) has not shown any remarkable changes; the γM concentration has varied slightly, the γG concentration has varied in relation to the injections of exogenous γG , and γA has not been detected. It must be noted, however, that the amount of 7 S antibody formed in response to injection of $\emptyset X$ in this patient has steadily increased. This may be the result of repeated immunization but also could indicate a change in the patient's immunological status during the period of study. Finally, a third possibility is that the normal controls of 19 S antibody synthesis are not operative in the patient, and in their absence the full capability of the 19 S system is revealed. It has been shown by Finkelshtein and Uhr (8) in guinea pigs that the production of 19 S antibody can be inhibited by passive administration of 7 S antibody. Similar results have been obtained in other immunization systems in rabbits (9) and in humans (10). Hence, it is possible that 7 S antibody persisting from the primary response may inhibit a potential secondary 19 S response. In patients with type I dysgammaglobulinemia the marked deficiency of γG - and γA -globulins may allow γM antibody production to occur largely free of the inhibitory effects of γG antibody. None of these three possibilities can be entirely excluded although on the basis of the available data one might prefer the last explanation.

Although the slowly sedimenting γM in this patient's serum appears to be a naturally occurring component among her γ -globulins, its relation to 19 S γM is not clear. Killander (31) obtained

suggestive evidence for the presence of low molecular weight γ M, and Rothfield, Frangione, and Franklin have described a slowly sedimenting γ M protein with antinuclear activity in the sera of patients with lupus erythematosus (32). A 7 S γ M has also been demonstrated in the sera of horses immunized with bacteria (33). Recently Solomon and Kunkel have reported in abstract (34) a patient with a low molecular γ M paraprotein. Several hypotheses have been advanced by Rothfield and associates (32) to explain the presence of light γ M. The protein may represent a γ M heavy chain or a subunit analogous to those produced by thiol reduction but not incorporated into the 19 S molecule. It may represent an *in vivo* or *in vitro* breakdown product of normal 19 S γ M. It may be a normal component of human γ -globulin, such as a monomer of 19 S containing both H and L chains. At the present time, a choice between these alternatives is not possible. Absorption of the slowly sedimenting antibody activity with antisera specific for the various immunoglobulins indicated that most of the antibody activity was associated with γ G. However, in view of the reductions after absorption with anti- γ M and anti- γ A, the presence of some activity associated with these immunoglobulins cannot be excluded. Finally, whether the immunoglobulins of this patient are analogous to the somewhat similar and intriguing immunoglobulins of the elasmobranch, *Mustelus canis* (smooth dogfish) (35), cannot be determined at this time.

Summary

Antibody formation in type I dysgammaglobulinemia, a syndrome characterized by deficiency of γ A- and γ G- and elevation of γ M-globulins, was studied by immunization with bacteriophage ϕ X 174. The bulk of the antibody formed was of the 19 S type even after five injections of antigen. However, after the second injection of antigen and thereafter significant amounts of γ G antibody were produced.

The increase in the magnitude of the 19 S antibody response on repeated immunization indicates that the 19 S antibody-forming mechanism developed long-lasting immunological "memory." Previous failures to demonstrate on γ M anamnestic response to viral antigens in guinea pigs and

rabbits may be related to the inhibitory effects of γ G antibody on γ M antibody production.

A slowly sedimenting γ M protein was demonstrated in the patient's serum by sucrose density gradient ultracentrifugation and gel filtration on G-200 Sephadex. The significance of the light γ M in immunological responsiveness and its place in 19 S γ M metabolism require further investigation.

Acknowledgment

Mr. William Dolan gave invaluable technical assistance.

References

1. Rosen, F. S., S. V. Kevy, E. Merler, C. A. Janeway, and D. Gitlin. Recurrent bacterial infections and dysgammaglobulinemia; deficiency of 7S gamma-globulins in the presence of elevated 19S gamma-globulins. *Pediatrics* 1961, **28**, 182.
2. Hong, R., W. K. Schubert, E. V. Perrin, and C. D. West. Antibody deficiency syndrome associated with beta-2 macroglobulinemia. *J. Pediat.* 1962, **61**, 831.
3. Rosen, F. S., and J. A. Bougas. Acquired dysgammaglobulinemia. Elevation of the 19S gamma globulin and deficiency of 7S gamma globulin in a woman with chronic progressive bronchiectasis. *New Engl. J. Med.* 1963, **269**, 1336.
4. Huntley, C. C., J. W. Lafferty, and A. Lysterly. Antibody deficiency syndrome with increased gamma₁ M (β_2 M) globulins and absent gamma₁ A (β_2 A) and gamma₂ (G) globulins. *Pediatrics* 1963, **32**, 407.
5. Gleich, G. J., J. J. Condemi, and J. H. Vaughan. Dysgammaglobulinemia in the presence of plasma cells. *New Engl. J. Med.* 1965, **272**, 331.
6. Barth, W. F., R. Asofsky, T. J. Liddy, Y. Tanaka, D. S. Rowe, and J. L. Fahey. An antibody deficiency syndrome. Selective immunoglobulin deficiency with reduced synthesis of γ and α immunoglobulin polypeptide chains. *Amer. J. Med.* 1965, **39**, 319.
7. Bauer, D. C., and A. B. Stavitsky. On the different molecular forms of antibody synthesized by rabbits during the early response to a single injection of protein and cellular antigens. *Proc. nat. Acad. Sci. (Wash.)* 1961, **47**, 1667.
8. Finkelstein, M. S., and J. W. Uhr. Specific inhibition of antibody formation by passively administered 19S and 7S antibody. *Science* 1964, **146**, 67.
9. Sahiar, K., and R. S. Schwartz. Inhibition of 19S antibody synthesis by 7S antibody. *Science* 1964, **145**, 395.
10. LoSpalluto, J., and C. W. Fink. Effect of prior administration of 7S and 19S antibody on antibody

- formation (abstract). *Arth. and Rheum.* 1964, 7, 324.
11. Uhr, J. W., and M. S. Finkelstein. Antibody formation. IV. Formation of rapidly and slowly sedimenting antibodies and immunological memory to bacteriophage ϕ X 174. *J. exp. Med.* 1963, 117, 457.
 12. Svehag, S., and B. Mandel. The formation and properties of poliovirus neutralizing antibody. II. 19S and 7S antibody formation: differences in antigen dose requirement for sustained synthesis, anamnesis, and sensitivity to X-irradiation. *J. exp. Med.* 1964, 119, 21.
 13. Uhr, J. W., M. S. Finkelstein, and E. C. Franklin. Antibody response to bacteriophage ϕ X 174 in non-mammalian vertebrates. *Proc. Soc. exp. Biol. (N. Y.)* 1962, 111, 13.
 14. Uhr, J. W., M. S. Finkelstein, and J. B. Baumann. Antibody formation. III. The primary and secondary antibody response to bacteriophage ϕ X 174 in guinea pigs. *J. exp. Med.* 1962, 115, 655.
 15. Uhr, J. W., J. Dancis, E. C. Franklin, M. S. Finkelstein, and E. W. Lewis. The antibody response to bacteriophage ϕ X 174 in newborn premature infants. *J. clin. Invest.* 1962, 41, 1509.
 16. Cone, L., and J. H. Uhr. Immunological deficiency disorders associated with chronic lymphocytic leukemia and multiple myeloma. *J. clin. Invest.* 1964, 43, 2241.
 17. Rowe, D. S., and J. L. Fahey. A new class of human immunoglobulins. II. Normal serum IgD. *J. exp. Med.* 1965, 121, 185.
 18. Finger, I., and E. A. Kabat. A comparison of human antisera to purified diphtheria toxoid with antisera to other purified antigens by quantitative precipitin and gel diffusion techniques. *J. exp. Med.* 1958, 108, 453.
 19. Rubinstein, H. M. Quantitative antigen analysis by the Oudin method. *J. Immunol.* 1954, 73, 322.
 20. Leddy, J. P., R. W. Hill, S. N. Swisher, and J. H. Vaughan. Observations on the immunochemical nature of red blood cell autosensitization. Immunopathology, Third International Symposium, P. Grabar and P. Miescher, Eds. Basel, Switzerland, Schwabe, 1963, p. 318.
 21. Adams, M. H. Bacteriophages. New York, Interscience, 1959.
 22. Kunkel, H. G. Macroglobulins and high molecular weight antibodies in Plasma Proteins, F. W. Putnam, Ed. New York and London, Academic Press, 1960, vol. 1, p. 295.
 23. Chance, B. Special methods in Methods of Biochemical Analysis, D. Glick, Ed. New York, Interscience, 1954, vol. 1, p. 408.
 24. Allen, P. Z., S. Sirisinha, and J. H. Vaughan. Immunochemical studies on equine antibodies to human γ_2 -globulin. *J. Immunol.* 1965, 95, 918.
 25. Mancini, G., A. O. Carbonara, and J. F. Hermans. Immunochemical quantitation of antigens by single radial immunodiffusion. *Immunochemistry* 1965, 2, 235.
 26. Fudenberg, H. H., and H. G. Kunkel. Physical properties of the red cell agglutinins in acquired hemolytic anemia. *J. exp. Med.* 1957, 106, 689.
 27. Leddy, J. P., and J. H. Vaughan. Unpublished observations.
 28. Nossal, G. J. V., G. L. Ada, and C. M. Austin. Antigens in immunity. VII. Analysis of immunological memory. *Immunology* 1965, 9, 333.
 29. Borel, Y., M. Fauconnet, and P. A. Miescher. 7S versus 19S anamnestic response in rabbits. *Proc. Soc. exp. Biol. (N. Y.)* 1964, 117, 603.
 30. Barth, W. F., R. D. Wochner, T. A. Waldmann, and J. L. Fahey. Metabolism of human gamma macroglobulins. *J. clin. Invest.* 1964, 43, 1036.
 31. Killander, J. Separation of human immunoglobulins by gel filtration and zone electrophoresis. *Acta Soc. Med. upsalien.* 1963, 68, 230.
 32. Rothfield, N. F., B. Frangione, and E. C. Franklin. Slowly sedimenting mercaptoethanol-resistant antinuclear factors related antigenically to M immunoglobulins (γ_{1M} -globulin) in patients with systemic lupus erythematosus. *J. clin. Invest.* 1965, 44, 62.
 33. Sandor, G., S. Korach, and P. Mattern. 7S globulin, immunologically identical to 19 S gamma-1 (beta-2)-M-globulin, a new protein of horse serum. *Nature (Lond.)* 1964, 204, 795.
 34. Solomon, A., and H. G. Kunkel. A "monoclonal" type low-molecular weight protein related to γ_M macroglobulins (abstract). *Blood* 1965, 26, 880.
 35. Marchalonis, J., and G. M. Edelman. Phylogenetic origins of antibody structure. I. Multichain structure of immunoglobulins in the smooth dogfish (*Mustelus canis*). *J. exp. Med.* 1965, 122, 601.